MergerJul 14, 2026, 05:41 PM
Glucotrack Completes Merger with Lōkahi Therapeutics
AI Summary
Glucotrack, Inc. announced the completion of its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed platform for healthcare asset identification and advancement. Lōkahi Therapeutics will become the operating and controlling business, with its securityholders expected to hold approximately 90% of the combined company on a fully diluted basis. A planned private placement financing will support the combined entity, while Glucotrack's legacy continuous blood glucose monitoring (CBGM) business will operate as a wholly owned, separate subsidiary. Erik Emerson has been appointed CEO of the combined company, and Paul Goode will serve as CTO and CEO of the CBGM subsidiary.
Key Highlights
- Glucotrack completed its strategic business combination with Lōkahi Therapeutics.
- Lōkahi Therapeutics becomes the operating and controlling business of the combined company.
- Lōkahi securityholders to hold approximately 90% of the combined company on a fully diluted basis.
- Transaction supported by a planned private placement financing to strengthen capital.
- Glucotrack's CBGM business will operate as a wholly owned subsidiary with separate operations.
- Erik Emerson appointed Chief Executive Officer of the combined company.
- Paul Goode appointed Chief Technical Officer of combined company and CEO of CBGM subsidiary.
Price Impact
More from GCTK